Bioxytran (BIXT) Cash from Investing Activities (2010 - 2026)
Bioxytran (BIXT) posted Cash from Investing Activities of -$9227.0 for Q1 2026, down 47.87% sequentially from -$6240.0 in Q4 2025, and down 61413.33% YoY from N/an in Q1 2025.
Bioxytran (BIXT) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Bioxytran has reported Cash from Investing Activities for 10 years, with the latest figure at -$9227.0 in Q1 2026.
- Quarterly Cash from Investing Activities fell 61413.33% year-over-year to -$9227.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32303.0 (down 45.42% YoY) and the FY2025 annual result came in at -$23091.0, up 18.1% from the prior year.
- Cash from Investing Activities eased to -$9227.0 in Q1 2026 per BIXT's latest filing, from -$6240.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $693.0 in Q2 2024 and troughed at -$22323.0 in Q1 2022.
- A 5-year average of -$8062.4 and a median of -$6561.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities jumped 103.41% in 2024, then slumped 61413.33% in 2026.
- Over 5 years, Cash from Investing Activities stood at -$2096.0 in 2022, then plunged by 213.02% to -$6561.0 in 2023, then plunged by 83.98% to -$12071.0 in 2024, then soared by 48.31% to -$6240.0 in 2025, then sank by 47.87% to -$9227.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$9227.0, -$6240.0, and -$1674.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | -9,383.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,227.00 |
| Mar 31, 2026 | -9,227.00 |
| Dec 31, 2025 | -6,240.00 |
| Dec 31, 2025 | -6,240.00 |
| Sep 30, 2025 | -1,674.00 |
| Sep 30, 2025 | -1,674.00 |
| Jun 30, 2025 | -15,162.00 |
| Jun 30, 2025 | -15,162.00 |
| Mar 31, 2025 | -15.00 |
| Mar 31, 2025 | -15.00 |
| Dec 31, 2024 | -12,071.00 |
| Dec 31, 2024 | -12,071.00 |
| Sep 30, 2024 | -10,821.00 |
| Sep 30, 2024 | -10,821.00 |
| Jun 30, 2024 | 693.00 |
| Jun 30, 2024 | 693.00 |
| Mar 31, 2024 | -5,995.00 |
| Mar 31, 2024 | -5,995.00 |
| Dec 31, 2023 | -6,561.00 |
| Dec 31, 2023 | -6,561.00 |